Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
This trial is a phase I/IIa study to assess the use of a [90Y]-labelled anti-CD66 as the sole conditioning prior to autologous stem cell transplant conditioning in patients with AL-amyloidosis. The main objective will be to determine the safety and toxicity associated with the use of the [90Y]-labelled anti-CD66 as measured by CTCAE version 4.0 criteria and stem cell engraftment and hence establish the maximum tolerated radiation dose (MTD) over three infused radiation activity levels.
Inclusion criteria
- AL Amyloidosis